Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL17515075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL29039567 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL31697543 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL29369526 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL29488544 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL82829 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL1650339 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL1660800 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3040814 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL3670606 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116763797-A | Pharmaceutical combination microsphere, preparation method thereof and raw material composition thereof | 上海医药工业研究院有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-20260048029-A1 | METHODS OF TREATING ANEMIA USING FORMOTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DANA FARBER CANCER INST INC (US) | 2026-02-19 | — | — | US | disclosed |
| CN-120076800-A | Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof | 丹娜法伯癌症研究院 | 2025-05-30 | — | — | CN | disclosed |
| CN-118976045-A | Pharmaceutical composition | 国立大学法人福井大学 | 2024-11-19 | — | — | CN | disclosed |
| CN-114650828-B | Pharmaceutical composition | 国立大学法人福井大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-118416094-A | Pharmaceutical composition | 国立大学法人福井大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20240252475-A1 | TIOTROPIUM COMBINATION PRODUCT COMPOSITIONS AND RELATED METHODS | SOMERSET THERAPEUTICS, LLC | 2024-08-01 | — | — | US | disclosed |
| WO-2024097413-A1 | METHODS OF TREATING ANEMIA USING FORMOTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-9446055-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| CN-103338789-A | Pharmaceutical composition containing poorly water-soluble drug | KOWA CO | 2013-10-02 | — | — | CN | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20090312380-A1 | NOVEL COMPOSITIONS AND METHODS | GENERICS [UK] LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| EP-2056875-A1 | NOVEL COMPOSITIONS AND METHODS | Generics (UK) Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008026012-A1 | NOVEL COMPOSITIONS AND METHODS | GENERICS [UK] LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048029-A1 | METHODS OF TREATING ANEMIA USING FORMOTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIOK2, NR3C2, RIOK1 | ADRB2 271/4885ADRB1 486/4885ADRB3 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.